Understanding how certain colorectal cancers respond to a specific cancer treatment
Analyzing the Hypersensitivity of MMR-deficient Colorectal Cancers to mTOR Inhibition and the Response of Cancer Stem Cells
This study is looking at how a drug called rapamycin might help treat colorectal cancers that don't fix DNA mistakes properly, using a special mouse model to see how these tumors behave and respond to the treatment, which could lead to better options for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11042264 on NIH RePORTER |
What this research studies
This research investigates the effects of mTOR inhibition on colorectal cancers that lack DNA mismatch repair (MMR) functionality. By using a unique mouse model that mimics human colorectal cancer, the study aims to determine how these cancers respond to treatment with rapamycin, a drug that has shown promising results in preliminary tests. The research focuses on the differences in tumor behavior between MMR-deficient and MMR-proficient cancers, providing insights into potential new treatment strategies for patients with these specific cancer types.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer that has been identified as MMR-deficient.
Not a fit: Patients with MMR-proficient colorectal cancers may not benefit from the findings of this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with MMR-deficient colorectal cancers.
How similar studies have performed: Preliminary studies have shown promising results with similar approaches, indicating that this line of investigation could be fruitful.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Edelmann, Winfried — Albert Einstein College of Medicine
- Study coordinator: Edelmann, Winfried
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.